CCL13

Across TCGA pan-cancer cohorts, CCL13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL13 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CCL13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL13 expression acts as an unfavorable survival marker.

LIHC and SKCM are the cancer types where CCL13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SKCM	OS	Median	All	0.257	0.781	.015	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCL13–LIHC (OS)

Open the LIHC breakdown →